Another PP, PTPRG, has been validated as a regulator of the response to second-generation TKIs in a newly diagnosed cohort of 66 CML patients, with the detection of higher mRNA level after 9 months of nilotinib treatment. Here, PTPRG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.